The paper evaluates the efficacy of the newer anticonvulsant lamotrigine in a developmentally disabled patient population. A retrospective evaluation was done at two institutional centres to assess adjunctive lamotrigine (Lamictal ) efficacy in a developmentally disabled population. Mean seizure frequency was compared between a 2-month pre-lamotrigine baseline period and a 2-month treatment period. A 3-month lamotrigine titration phase occurred between baseline and treatment periods. Seizure frequency data was obtained from standardized, daily seizure records. Adverse effect data was obtained from medical and nursing notes. An intent to treat analysis was performed. Data were analysed using Student's t-test for paired data. We evaluated 44 centre residents (25 male, 19 female, average age 33 ± 11 years). Mean lamotrigine dose was 272 ± 133 mg per day. A significant reduction in seizure frequency was noted. Seizure frequency (all seizures) was 10.1 ± 11.2 during the baseline period vs. 5.8 ± 7.9 seizures per month during the treatment period (P = 0.002). Thirty-two percent of patients (n = 14) had greater than a 75% reduction in seizure frequency. Twenty-three percent of patients (n = 10) had a 50-74% seizure reduction. Twentyfive percent of patients (n = 11) had less than a 50% reduction in seizures, while 20% (n = 9) had an increase in seizures. A significant reduction of 48% in generalized seizures (9.5 ± 11.6 vs. 4.9 ± 6.5 seizures per month, P = 0.013) was noted. Reductions in partial seizure frequency of 48% (7.9 ± 10 vs. 4 ± 6.6 seizures per month, P = 0.16) as well as in mixed-type seizures (19.9 ± 9.3 was vs. 15 ± 12.1 seizures per month, P = 0.11) were also seen; however, these changes did not reach significance. Overall, lamotrigine was well tolerated by the subject population. Adjunctive treatment with lamotrigine appears to be an efficacious and well-tolerated treatment for seizures in a significant percentage of developmentally disabled patients with epilepsy.
INTRODUCTION
Epilepsy is a common co-morbidity in approximately 20-50% of patients with mental retardation and developmental disabilities. Epilepsy in these patients is complex and patients may present with multiple seizure types including partial, as well as generalized seizures 1 . In addition, many of these patients have intractable, or incompletely controlled seizures 2 . More than 63% of patients in residential care facilities have severe cerebral palsy in addition to mental retardation and epilepsy. These patients may have sensory impairments, behaviour disturbances, psychiatric disorders, and other medical abnormalities 3 . Patients with cerebral palsy have a higher incidence of epilepsy than patients without, and epilepsy is an indicator of cerebral palsy severity. Frequently, seizures encountered in these patients are intractable to treatment with the older antiepileptic drugs (AEDs). In addition to seizure intractability to available medi-cations, determination of a specific seizure-type diagnosis can be difficult, and neurologic impairments such as mental retardation potentially increases susceptibility to cognitive adverse effects attributable to AEDs 1 . Both mood and behaviour may be worsened by AEDs in these patients. In this population, polytherapy with older AEDs, including barbiturates has been common 4 . Pellock and Hunt reported that removal of sedating drugs such as phenobarbital resulted in decreased sedation, aggression and irritability 4 .
The ideal AED for the treatment of epilepsy in patients with developmental handicaps would have efficacy against both partial and generalized seizures, minimal adverse cognitive and behavioural effects, and minimal pharmacokinetic drugs interactions 5 . Since 1993, five new AEDs have been introduced to the US market, and the usage of these drugs instead of the older antiepileptics is debated 6 . In particular, the role of these newer agents in the treatment of refractory seizures in patients with severe developmental disabilities is still unclear.
Lamotrigine (LTG) is a novel antiepileptic drug that is indicated for the adjunctive and monotherapy 7 treatment of partial seizures with and without secondary generalization. Lamotrigine is also approved for use in patients with seizures associated with LennoxGastaut syndrome 8, 9 . Efficacy in the treatment of absence seizures has also recently been suggested 10 . Although the adjunctive use of LTG for refractory partial seizures has been well established, data regarding the specific use of LTG in severely retarded, developmentally disabled patients is limited.
Given its favourable cognitive and neurotoxic adverse effect profile, as well as its demonstrated efficacy as adjunctive treatment for refractory complex-partial seizures, LTG may be a useful agent in this unique clinical setting.
The primary objective of the present retrospective evaluation was to evaluate the efficacy of LTG in developmentally disabled patients with epilepsy. In addition, any adverse reactions attributable to LTG administration and necessitating drug discontinuation were identified.
MATERIALS AND METHODS

Patients
Medical and pharmacy records were reviewed to identify all patients who had, or were receiving LTG, during the period 1995-1996. All patients having a diagnosis of mental retardation (profound mental retardation, IQ < 20), developmental disabilities and epilepsy, with seizure type documented prior to evaluation using ILAE classification 11 , were included in this evaluation. Study patients were evaluated in two clinical sites (Seattle, WA and Madison, WI).
Drug dosage and escalation
Lamotrigine therapy was initiated based upon clinical indication, and the final drug dosage was at the discretion of the attending physician. During the period of study evaluation, LTG serum concentration determinations were not routinely performed. Patients had no prior exposure to LTG.
Assessment and evaluation
This study was designed to include both retrospective and concurrent observation, with each patient serving as their own control. Our review was structured a priori with respect to outcome measures and time frame. This evaluation consisted of three phases. Phase 1 consisted of a baseline period of 2-months preceding LTG initiation. Baseline and on-treatment seizure frequency were recorded daily using a standardized format by nursing and residential care staff. Phase 2 was designated as the drug escalation period. Three months were allowed for LTG dosage escalation. This time period was chosen to be consistent with package insert dosing guidelines. Phase 3 was the treatment observation period, which corresponded to months 4 and 5 on medication. The total study evaluation period, therefore, was 7 months. The primary outcome measure for this evaluation was a change in seizure frequency. The percentage change in seizure frequency was calculated as follows: (treatment period average − baseline average)/baseline average × 100. Adverse effect data were obtained from nursing and medical progress notes. Seizure types were categorized as either generalized, partial, or mixed. Differences in the seizure frequency are compared between Phase 1 (baseline period) and Phase 3 (treatment period) using the Student's t-test for paired data. Statistical significance was assigned at a P < 0.05. All data are presented as mean ± SD. An intent-to-treat analysis was used in this evaluation. This study was approved by the institutional review board at each site prior to the study initiation.
RESULTS
The overall study group (n = 44) consisted of 25 men and 19 women, with a mean age of 33.5 ± 11 years (8-59 years). All the patients had profound mental retardation (IQ < 20). The average number of years since the onset of seizures was 32. Mean LTG dose was 272 ± 133 mg per day. Concomitant AEDs included carbamazepine (n = 16), phenytoin (n = 14), phenobarbital (n = 6), primidone (n = 1), valproic acid (n = 12), clonazepam (n = 4), ethosuximide (n = 2), gabapentin (n = 6), felbamate (n = 1). Between baseline and end-of-treatment evaluation period, dosages of concomitant AEDs remained unchanged in 21 patients. Dosages of concomitant AEDs were reduced in 21 patients (carbamazepine = 10, valproic acid = 7, phenytoin = 4), and increased in two individuals (phenytoin = 2).
Of the overall study group, 24 patients (17 men and 7 women, 31 ± 12 years, 8-59 years) had generalized seizures including tonic-clonic, tonic, atonic and myoclonic seizures. These individuals had symptomatic generalized epilepsies as opposed to idiopathic epilepsy. Fifteen patients had partial seizures (seven men and eight women, 36.3 ± 8.8 years, 22-53 years old). Five patients (one man and four women, 37.2 ± 10.3 years, 29-55 years old) were classified as having a mixed seizure disorder (Fig. 1) .
Overall, a seizure frequency reduction of >75% was seen in 32% (n = 14) of patients (Table 1) . A 50-74% reduction in seizure frequency was seen in 23% (n = 10). A 25-49% reduction in seizure frequency was seen in 11% of patients (n = 5). Fourteen percent of the patients (n = 6) had between zero and 24% reduction in seizure frequency. Twenty-one percent of patients were noted to have an increase in seizure frequency. When all seizures are considered, a statistically significant reduction was noted between baseline and treatment period (10.2 ± 11.2 vs. 5.8 ± 7.8 seizures per month, P = 0.002). Significant reductions of 48% were noted in the frequency of generalized tonic-clonic seizures (9.5±11.6 vs. 4.9 ± 6.5 seizures per month, P = 0.013) (Table 2). Although partial seizures were reduced 48% from baseline (7.9 ± 10 vs. 4.1 ± 6.6 seizures per month), this change failed to achieve statistical significance (P = 0.16), perhaps reflecting the relatively small sample size. Similarly, for mixed-type seizures, there was a non-significant reduction in seizure frequency (19.9 ± 9.3 vs. 15 ± 12.1 seizures per month, P = 0.11). Six patients (13%), each of whom had at least one seizure during baseline, were seizure free during the treatment evaluation period. No episodes of status epilepticus occurred during any phase of observation.
Few treatment-emergent adverse drug effects were noted. Gastrointestinal symptoms (vomiting) were noted in two patients, and led to drug discontinuation. Of the 44 patients evaluated, five were noted to display self-injurious behaviours at baseline. Following LTG treatment, three patients displayed an increase in these behaviours which resulted in discontinuation of LTG. No serious biochemical abnormalities or rash were noted. Clinically significant increases or changes in sedation were not noted. In general, LTG was well tolerated in this population. Overall, treatment was discontinued due to adverse effects in 11% of patients.
DISCUSSION
Our data suggests that LTG may be a useful adjunctive medication in this difficult population, and is in general agreement with other, albeit limited, experience. In an early report, Uvebrant and Bauziene described their experience with LTG in 45 children with mental retardation, autism, attention deficit disorder or other severe neurological or neuropsychiatric impairments 12 . Concurrent LTG therapy for a mean of 14 months resulted in complete seizure control in 11% of patients. An additional 36% demonstrated a >30% reduction in seizure frequency. Seizure control did not improve in over half the patients studied. The most common adverse events encountered were sleep disturbance and rash.
King et al. 13 conducted a retrospective chart review of 53 developmentally disabled patients treated with LTG and reported responder rates in the symptomatic, mixed, generalized, and difficult to classify seizures that were comparable to the present study. Overall, 53% of patients demonstrated greater than 50% improvement in seizure frequency. Similar to our experience there were no cases of rash, haematological effects, nor status epilepticus. Treatment-emergent adverse effects did not lead to drug discontinuation in any patient.
In a retrospective review of adults with learning disabilities and refractory seizures, Bhaumik et al. 14 compared the outcome of administration of three AEDs (LTG, gabapentin and vigabatrin). Efficacy rates were similar between the individual agents. With respect to LTG, the duration of treatment was 13 months (range 1-36 months). Of the 25 patients receiving LTG (mean age 36 ± 9 years, 60% severeprofound MR), 36% of the patients on LTG were shown to have a greater than 50% seizure reduction in add-on therapy. None of the patients became seizurefree. Increased seizure frequency was seen in 24% of patients, and the authors note that this may have been associated with larger doses of LTG. Although an increase in seizure frequency was noted in a similar number of patients in the present study (21%); no relationship to LTG dose was apparent. Twenty-eight percent of the patients (n = 7) experienced adverse effects that included rash (n = 2), behaviour problems (n = 2), persistent vomiting (n = 1), and unsteady gait (n = 1). Of note, one patient did develop StevenJohnson syndrome.
In an open trial 15 of 37 mentally retarded children and adolescents treated with LTG for a median of 7 months, a seizure reduction of between 50 and 100% was seen in 35% of patients. The authors note that efficacy may have been greater in children suffering from primary generalized seizures.
Sorensen 16 reviewed 200 mentally retarded patients (n = 54 profound MR) treated with LTG for a mean duration of 17 ± 2.2 months (range 1-65 months). Fifty-eight percent of the patients had a greater than 50% improvement in seizure frequency. Twenty-three percent of the patients were noted to have LTG therapy discontinued due to either lack of efficacy (including increased seizures) or adverse effects. Behavioural and/or psychiatric adverse effects were noted in approximately 22% of patients. Rash was observed in 5%.
Finally, in an interim analysis of a prospective trial, McKee et al. 17 reported that in 33 mentally retarded (82% severe-profound MR) patients treated with LTG for 36 weeks, 36% of patients had a 50% reduction in seizure frequency. While 15% of patients did become seizure free, 10-15% of patients showed a worsening in behaviour and/or functional status.
There are numerous issues involved in the treatment of this particular patient population. These patients may have multiple physical and psychiatric/psychological problems, and may be receiving multiple medications that potentially result in pharmacokinetic or pharmacodynamic interactions. In addition, these patients may continue to have seizures despite multiple AED combinations. Assessment of seizure activity, particularly complex-partial seizures, may be complicated or confused with individual patient behavioural or psychological symptoms. For similar reasons, assessment of drug-related adverse effects is difficult in this population 1 . Assessment of potential drug toxicity is also confounded by the diminished capacity of these patients to communicate. In general, LTG was well tolerated and the adverse effects noted in our study are consistent with previously published experience. Interestingly, treatment-emergent rash was not observed in any patient. Data from clinical trials and post-marketing surveillance studies suggest that rash may occur in approximately 10% of adult patients treated with LTG. Rapid drug escalation and concomitant treatment with valproic acid may increase the likelihood of rash 18, 19 . Conceivably, the slow, judicious dosage titration rates used in our patients were responsible for the absence of this side-effect.
Adverse events such as increased aggression and behavioural deterioration may be somewhat unique to this population. Beran and Gibson 20 reported survey data on behaviour changes during LTG treatment and found 47.4% of patients exhibited aggressive behaviour thought related to LTG. The mean age of these patients was 33.9 ± 8.91 years. No related aggression was found in 10 patients (52.6%). This aggression occurred within 1 month of initiation at low titration doses. In the present study, five patients displayed self-injurious behaviours at baseline. After the initiation and titration of LTG, three patients (6.8%) displayed an increase in these behaviours requiring discontinuation.
As noted previously, aggression and/or adverse behavioural changes have been observed by other investigators. While these behavioural effects certainly do appear to be associated with LTG in these patients, determining the underlying mechanism(s) of behavioural changes may not be straight forward. In many cases, these patients may be non-verbal, and hence, unable to express their feelings. This is particularly true in the profoundly impaired patient. Since LTG is frequently used as adjunctive treatment in these largely refractory patients, it is conceivable that the occurrence of common adverse neurosensory effects may be expressed differently in a non-verbal patient. Besag et al. 21 have recently noted behavioural disturbance as a possible manifestation of an adverse pharmacodynamic interaction between carbamazepine and LTG in a learningdisabled population. Clearly, these issues merit further investigation.
CONCLUSION
Our observations suggest that LTG can play a positive role in the care of these developmentally disabled persons with epilepsy. At present, although a substantial body of literature exists documenting both the efficacy and tolerability of LTG in adult ambulatory patients with partial seizures, little data exist in the profoundly impaired, institutionalized epilepsy patient. The relationship between randomized, controlled clinical trials done to secure drug licensing may not reflect everyday clinical practice, or be generalizable to unique populations such as ours 22 . With that in mind, we must acknowledge possible limitations of the present study. Although this study was retrospective, several elements were incorporated into this study design that lend it strength. Baseline and treatment observation periods were established a priori, and intent-to-treat assumption was made prior to data analysis. While seizure assessment may be problematic in these patients, both centres involved in this trial used standardized seizure records that were maintained daily by trained personnel. Unfortunately, no such standardized, systematic assessment tool for adverse effects was in use at the time of this evaluation. While nursing and medical notes were extensive, the potential for reporting bias does exist.
Clearly, further investigations aimed toward identifying patient characteristics that may predispose to untoward adverse behavioural effects would be helpful. In addition, further information regarding both pharmacokinetic as well as pharmacodynamic interactions in this population would be useful. For example, the combination of LTG and valproic acid has been reported to be a particularly useful, possibly synergistic combination in patients with refractory partial seizures 23, 24 . Unfortunately, we lacked sufficient power to discern specific differences in efficacy between various drug combinations. Data from ongoing, prospective trials should further clarify these issues.
